Palvella Therapeutics (PVLA) said Wednesday that first patients have been dosed in the phase 2 clinical trial of Qtorin 3.9% rapamycin anhydrous gel to treat cutaneous venous malformations.
Venous malformation is the underdevelopment of veins in the body that can lead to abnormal blood vessels.
The company said the study is expected to enroll about 15 patients at least six years old across the US to evaluate the safety and efficacy of Qtorin administered topically once daily.
According to Palvella, the US Food and Drug Administration granted fast track designation to the drug in April 2024.
Price: 14.45, Change: -0.28, Percent Change: -1.90
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。